Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash Article

cited authors

  • Schilder, Russell J., Pathak, Harsh B., Lokshin, Anna E., Holloway, Robert W., Alvarez, Ronald D., Aghajanian, Carol, Min, Hua, Devarajan, Karthik, Ross, Eric, Drescher, Charles W., Godwin, Andrew K.

abstract

  • Objectives. Determine if cetuximab dose escalation to induce grade 2 rash correlates with anti-tumor activity and if sera-based markers could predict likelihood of response. Methods. Patients with persistent/recurrent ovarian or primary peritoneal carcinoma received an initial dose of cetuximab 400 mg/m(2), then 250 mg/m(2) weekly for two 3-week cycles. Patients who had stable disease (SD) and

authors

Publication Date

  • April 1, 2009

webpage

published in

category

start page

  • 21

end page

  • 27

volume

  • 113

issue

  • 1

WoS Citations

  • 64

WoS References

  • 73